View Older Stories View More Recent Stories

Nov 6, 2024 04:05PM Veracyte Announces Third Quarter 2024 Financial Results
Oct 30, 2024 05:00PM Veracyte to Participate in Upcoming Investor Conferences
Oct 16, 2024 06:43PM Veracyte to Release Third Quarter 2024 Financial Results on November 6, 2024
Oct 2, 2024 08:20AM New Data Presented at ASTRO 2024 Show that Veracyte’s Decipher Prostate Test Predicts Aggressive Prostate Cancer in African American Men
Sep 15, 2024 08:45AM New Data Presented at ESMO 2024 Show that Veracyte’s Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer
Sep 4, 2024 04:05PM Veracyte (VCYT) Appoints Brent Shafer and Tom Miller to its Board
Sep 4, 2024 04:05PM Veracyte Appoints Brent Shafer and Tom Miller, Ph.D., to Its Board of Directors
Aug 26, 2024 05:30PM Veracyte to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Aug 26, 2024 09:00AM Veracyte Named a Greater Bay Area Top Workplace by the San Francisco Chronicle
Aug 6, 2024 04:05PM Veracyte Announces Second Quarter 2024 Financial Results
Jul 17, 2024 05:00PM Veracyte to Release Second Quarter 2024 Financial Results on August 6, 2024
Jun 3, 2024 04:05PM Veracyte Announces that New Afirma GRID Data Suggest Prognostic Ability of Molecular Testing for Thyroid Tumors
May 22, 2024 04:05PM Veracyte Announces Multiple Afirma GRID Presentations at ENDO 2024, Previewing the Future of Molecular Testing in Thyroid Nodules and Cancer
May 15, 2024 05:04PM Veracyte to Participate in Upcoming Investor Conferences
May 7, 2024 04:05PM Veracyte Announces First Quarter 2024 Financial Results
May 6, 2024 04:05PM 14 Studies Presented at AUA 2024 Show Decipher Tests’ Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease Understanding
Apr 22, 2024 05:00PM Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024
Apr 22, 2024 08:30AM New Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance
Apr 16, 2024 08:30AM Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024
Feb 27, 2024 05:55PM Veracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines
Feb 22, 2024 04:05PM Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results
Feb 21, 2024 05:00PM Veracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference
Feb 8, 2024 08:00AM Veracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024
Feb 6, 2024 08:15AM Veracyte Completes Acquisition of C2i Genomics
Jan 8, 2024 08:09AM Veracyte (VCYT) Announces Preliminary Full-Year 2023 Results, Acquisition of C2i Genomics
Jan 8, 2024 08:00AM Veracyte Announces Preliminary Full-Year 2023 Results, Acquisition of C2i Genomics to Add Minimal Residual Disease Capabilities to Its Novel Diagnostics Platform
Dec 12, 2023 04:30PM Veracyte to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
Dec 1, 2023 04:05PM Real-World Data Presented at SUO 2023 Show that Veracyte’s Decipher Genomic Classifier Identifies Patients Whose Prostate Cancer is Likely to Progress
Nov 29, 2023 08:30AM Clinical Validation Data Published in CHEST Demonstrate that Veracyte’s Percepta Nasal Swab Test Improves Lung Cancer Risk Assessment for Patients with Lung Nodules
Nov 22, 2023 08:30AM Veracyte Announces Seven Posters Highlighting Clinical Value of Decipher Prostate Genomic Testing To be Presented at SUO 2023
Nov 7, 2023 04:05PM Veracyte Announces Third Quarter 2023 Financial Results
Nov 7, 2023 04:00PM Veracyte (VCYT) Announces In Vitro Diagnostic Agreement with Illumina (ILMN) to Broaden Availability of Its Tests for Patients Globally
Nov 7, 2023 04:00PM Veracyte Announces In Vitro Diagnostic Agreement with Illumina to Broaden Availability of Its Tests for Patients Globally
Nov 2, 2023 08:15AM Veracyte to Participate in the Stephens Annual Investment Conference
Oct 27, 2023 08:30AM Veracyte Announces SITC 2023 Presentations Offering New Insight into Immuno-oncology Drug Development
Oct 17, 2023 08:15AM Veracyte to Release Third Quarter 2023 Financial Results on November 7, 2023
Oct 12, 2023 09:00AM New Data Presented at CHEST 2023 Demonstrate the Clinical Utility of Veracyte’s Envisia Genomic Classifier for Patients with Interstitial Lung Disease
Oct 4, 2023 04:05PM Veracyte (VCYT) Reports New Data from Phase 3 Trial Further Validating Prognostic Value of Decipher Prostate Genomic Classifier
Oct 4, 2023 04:05PM New Data from Phase 3 Trial Further Validate Prognostic Value of Veracyte’s Decipher Prostate Genomic Classifier
Sep 28, 2023 04:05PM New Data Presented at the 2023 ATA Annual Meeting Demonstrate that Veracyte’s Afirma-Based Testing Can Uncover Key Molecular Hallmarks of Thyroid Cancer
Sep 28, 2023 08:15AM Veracyte Announces Multiple Studies Reinforcing the Value of Decipher Prostate Testing Will Be Presented at ASTRO 2023
Sep 27, 2023 09:00AM Veracyte (VCYT) Appoints Phillip G. Febbo as Chief Scientific Officer and Chief Medical Officer
Sep 27, 2023 09:00AM Veracyte Names Phillip G. Febbo, M.D., as Chief Scientific Officer and Chief Medical Officer
Sep 21, 2023 04:05PM Veracyte Announces Novel Afirma-Based Findings that Advance Molecular Understanding of Thyroid Cancer to Be Presented at the 2023 ATA Annual Meeting
Sep 7, 2023 04:05PM Veracyte Names Marie-Claire Taine, Ph.D., as General Manager of Its IVD Business Unit To Advance Global Expansion of the Company’s Tests
Sep 6, 2023 08:15AM Veracyte (VCYT) and Gustave Roussy Collaborate to Help Accelerate Development of Novel Cancer Therapies
Sep 6, 2023 08:15AM Veracyte and Gustave Roussy Announce Collaboration to Help Biopharmaceutical Companies Accelerate Development of Novel Cancer Therapies
Aug 29, 2023 08:15AM Veracyte to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
Aug 22, 2023 08:15AM Veracyte Announces that Findings Published in JCO Precision Oncology Suggest Potential of Decipher GRID-Derived Gene Signatures to Predict Treatment Response in Recurrent Prostate Cancer
Aug 15, 2023 04:15PM Veracyte Earns Top Workplace Awards in the San Francisco Bay Area and San Diego
View More Recent Stories View Older Stories